Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H38N2O7S |
| Molecular Weight | 546.676 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(OC)C(CNC(CC(O)=O)CC(O)=O)=C2)[C@H](N1)C3=CC=CC=C3
InChI
InChIKey=CZGVOBIGEBDYTP-VSGBNLITSA-N
InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
| Molecular Formula | C28H38N2O7S |
| Molecular Weight | 546.676 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
GSK-2330672 (linerixibat) is a nonabsorbable apical sodium-dependent bile acid transporter. This compound is being evaluated for treatment in patients with type 2 diabetes. In animal models of type 2 diabetes, it lowers glucose levels. GSK-2330672 also improves glucose and lipids in diabetes patients, but a high incidence of gastrointestinal adverse events (such as diarrhea) has been reported. Efficacy of GSK-2330672 in patients with primary biliary cholangitis that develop itch (pruritus) has also been examined. However, long-term used might be problematic because of the gastrointestinal adverse events.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:37:40 GMT 2023
by
admin
on
Sat Dec 16 08:37:40 GMT 2023
|
| Record UNII |
386012Z45S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
701919
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1345982-69-5
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
386012Z45S
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
DB11729
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
10729
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
100000181116
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
C166652
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
GH-32
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY | |||
|
53492727
Created by
admin on Sat Dec 16 08:37:40 GMT 2023 , Edited by admin on Sat Dec 16 08:37:40 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
